Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 13/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL700135 | 0.96 | BDKRB1 (0.47) | BDKRB1CNR1CCR2HSD11B1CYP11B1 | |
| SCHEMBL699865 | 0.90 | BDKRB1 (0.48) | BDKRB1CNR1CCR2HSD11B1 | |
| SCHEMBL3441787 | 0.89 | BDKRB1 (0.45) | BDKRB1CNR1CCR2CYP11B1CYP11B2 | |
| SCHEMBL703279 | 0.89 | BDKRB1 (0.49) | BDKRB1CNR1CCR2HSD11B1 | |
| SCHEMBL3441716 | 0.89 | BDKRB1 (0.45) | BDKRB1CNR1CCR2 | |
| SCHEMBL3441687 | 0.88 | BDKRB1 (0.46) | BDKRB1CNR1CCR2CYP11B1CYP11B2 | |
| SCHEMBL3441983 | 0.87 | BDKRB1 (0.46) | BDKRB1CNR1CCR2CYP11B1CYP11B2 | |
| SCHEMBL3442289 | 0.85 | BDKRB1 (0.46) | BDKRB1CNR1CCR2CYP11B1CYP11B2 | |
| SCHEMBL3441768 | 0.84 | BDKRB1 (0.47) | BDKRB1CNR1CCR2CYP11B1CYP11B2 | |
| SCHEMBL702160 | 0.80 | TACR1 (0.41) | CCR2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | claimed |
| US-20090264407-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | claimed |
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| US-20090264407-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264407-A1 | Substituted Sulfonamide Compounds | CNR1, SUCNR1, OPRL1 | BDKRB1 11/4885CNR1 1/4885CCR2 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.